BRPI0910368B8 - uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores - Google Patents

uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores

Info

Publication number
BRPI0910368B8
BRPI0910368B8 BRPI0910368A BRPI0910368A BRPI0910368B8 BR PI0910368 B8 BRPI0910368 B8 BR PI0910368B8 BR PI0910368 A BRPI0910368 A BR PI0910368A BR PI0910368 A BRPI0910368 A BR PI0910368A BR PI0910368 B8 BRPI0910368 B8 BR PI0910368B8
Authority
BR
Brazil
Prior art keywords
bioenhancers
photoenhancers
enhancers
chosen
enhancers chosen
Prior art date
Application number
BRPI0910368A
Other languages
English (en)
Inventor
Stagni Edoardo
Sodo Eugenio
Cavallo Giovanni
Stagni Marcello
Filippello Massimo
Original Assignee
Sooft Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910368(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sooft Italia Spa filed Critical Sooft Italia Spa
Publication of BRPI0910368A2 publication Critical patent/BRPI0910368A2/pt
Publication of BRPI0910368B1 publication Critical patent/BRPI0910368B1/pt
Publication of BRPI0910368B8 publication Critical patent/BRPI0910368B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de um ou mais biointensificadores composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores, é descrito no presente documento o uso de intensificadores com possível riboflavina, bem como as composições correspondentes para o tratamento de ceratocone ou outras doenças corneanas ectásicas por meio do método de ligação cruzada corneana.
BRPI0910368A 2008-08-28 2009-08-27 uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores BRPI0910368B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2008A000472A IT1393402B1 (it) 2008-08-28 2008-08-28 Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
ITRM2008A000472 2008-08-28
PCT/IT2009/000392 WO2010023705A1 (en) 2008-08-28 2009-08-27 Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders

Publications (3)

Publication Number Publication Date
BRPI0910368A2 BRPI0910368A2 (pt) 2015-10-13
BRPI0910368B1 BRPI0910368B1 (pt) 2020-01-28
BRPI0910368B8 true BRPI0910368B8 (pt) 2021-05-25

Family

ID=40679354

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910368A BRPI0910368B8 (pt) 2008-08-28 2009-08-27 uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores

Country Status (18)

Country Link
US (1) US20110152219A1 (pt)
EP (1) EP2323642B1 (pt)
JP (1) JP2012500844A (pt)
KR (1) KR20110046567A (pt)
CN (1) CN102164592B (pt)
AU (1) AU2009286285B2 (pt)
BR (1) BRPI0910368B8 (pt)
CL (1) CL2011000378A1 (pt)
DK (1) DK2323642T3 (pt)
EA (2) EA023607B1 (pt)
ES (1) ES2460578T3 (pt)
IL (1) IL211448A (pt)
IT (1) IT1393402B1 (pt)
MX (2) MX358176B (pt)
PE (1) PE20110287A1 (pt)
PL (1) PL2323642T3 (pt)
PT (1) PT2323642E (pt)
WO (1) WO2010023705A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227197A4 (en) 2007-12-05 2011-06-22 Avedro Inc EYE THERAPY SYSTEM
US8366689B2 (en) 2008-09-30 2013-02-05 Avedro, Inc. Method for making structural changes in corneal fibrils
WO2011050164A1 (en) 2009-10-21 2011-04-28 Avedro, Inc. Eye therapy
JP6377906B2 (ja) * 2010-03-19 2018-08-22 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． 眼治療を適用およびモニターするためのシステム
US20110280763A1 (en) * 2010-05-17 2011-11-17 Abbott Medical Optics Inc. Light-activated disinfection system
IT1400982B1 (it) * 2010-07-05 2013-07-05 Pinelli Collirio osmotico trans-epiteliale per la cura del cheratocono.
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
ES2590127T3 (es) * 2011-01-12 2016-11-18 Sooft Italia S.P.A. Administración corneal de agentes de entrecruzamiento por iontoforesis para el tratamiento de queratocono y composiciones oftálmicas relacionadas
US9700456B2 (en) 2011-01-12 2017-07-11 Sooft Italia Spa Device and method for corneal delivery of riboflavin by iontophoresis for the treatment of keratoconus
WO2012158991A2 (en) * 2011-05-18 2012-11-22 Avedro, Inc. Controlled application of cross-linking agent
WO2012162529A1 (en) 2011-05-24 2012-11-29 Avedro, Inc. Systems and methods for reshaping an eye feature
WO2012167260A2 (en) 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
ITRM20110560A1 (it) * 2011-10-25 2013-04-26 Sooft Italia Spa Migliorata composizione di cross-linking per il trattamento del cheratocono mediante iontoforesi
RU2481809C1 (ru) * 2011-12-21 2013-05-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения кератэктазии после лазик
ES2986057T3 (es) 2012-03-29 2024-11-08 Epion Therapeutics Inc Composiciones y métodos para tratar o prevenir enfermedades asociadas al estrés oxidativo
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
WO2013148895A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
RU2487691C1 (ru) * 2012-04-12 2013-07-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения кератоконуса
EP2872081B2 (en) 2012-07-16 2025-07-16 Avedro, Inc. Systems for corneal cross-linking with pulsed light
BR112015013825A2 (pt) * 2013-01-28 2017-07-11 Wavelight Gmbh aparelho e método para a reticulação da córnea, e, uso do aparelho para a reticulação da córnea
US20140343480A1 (en) * 2013-05-19 2014-11-20 Avedro, Inc. Systems, methods, and compositions for cross-linking
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9498122B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
RU2542799C1 (ru) * 2013-10-29 2015-02-27 Игорь Борисович Медведев Способ лечения кератоконуса роговицы
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
US10206569B1 (en) 2014-05-12 2019-02-19 Gholam A. Peyman Corneal intraocular pressure sensor and a surgical method using the same
US11565023B2 (en) 2014-05-12 2023-01-31 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US9937033B1 (en) 2014-05-12 2018-04-10 Gholam A. Peyman Corneal lenslet implantation with a cross-linked cornea
US10583221B2 (en) 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US10709546B2 (en) 2014-05-12 2020-07-14 Gholam A. Peyman Intracorneal lens implantation with a cross-linked cornea
US10925889B2 (en) 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11338059B2 (en) 2014-05-12 2022-05-24 Gholam A. Peyman Method of corneal and scleral inlay crosslinking and preservation
US10314690B1 (en) 2014-05-12 2019-06-11 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11666777B2 (en) 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
US10278920B1 (en) 2014-05-12 2019-05-07 Gholam A. Peyman Drug delivery implant and a method using the same
US11648261B2 (en) 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US10195081B1 (en) 2014-05-12 2019-02-05 Gholam A. Peyman Method of prevention of capsular opacification and fibrosis after cataract extraction and/or prevention of fibrosis around a shunt or stent after glaucoma surgery
US11045352B2 (en) 2014-05-12 2021-06-29 Gholam A. Peyman Methods for treatment of dry eye and other acute or chronic inflammatory processes
US12396889B2 (en) 2014-05-12 2025-08-26 Gholam A. Peyman Lamellar corneal autologous or homologous graft in refractive surgery
US9427355B1 (en) * 2014-05-12 2016-08-30 Gholam A. Peyman Corneal transplantation with a cross-linked cornea
US12383393B2 (en) 2014-05-12 2025-08-12 Gholam A. Peyman Ablatable corneal inlay for correction of refractive errors and/or presbyopia
US10881503B2 (en) 2014-05-12 2021-01-05 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11259914B2 (en) 2014-05-12 2022-03-01 Gholam A. Peyman Molding or 3-D printing of a synthetic refractive corneal lenslet
US9744029B1 (en) 2014-05-12 2017-08-29 Gholam A. Peyman Method of preventing capsular opacification and fibrosis utilizing an accommodative intraocular lens implant
KR102545628B1 (ko) 2014-10-27 2023-06-20 아베드로 인코퍼레이티드 눈의 교차-결합 처리를 위한 시스템 및 방법
WO2016077747A1 (en) 2014-11-13 2016-05-19 Avedro, Inc. Multipass virtually imaged phased array etalon
EP3285704B1 (en) 2015-04-24 2020-11-18 Avedro Inc. Systems for photoactivating a photosensitizer applied to an eye
HUE040373T2 (hu) 2015-04-29 2019-03-28 Sooft Italia S P A Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra
US10028657B2 (en) 2015-05-22 2018-07-24 Avedro, Inc. Systems and methods for monitoring cross-linking activity for corneal treatments
KR102706856B1 (ko) 2015-07-21 2024-09-19 아베드로 인코퍼레이티드 광증감제로 눈을 치료하기 위한 시스템 및 방법
CN105256059B (zh) * 2015-11-20 2019-01-18 山东省眼科研究所 Tuba3d基因在制备圆锥角膜诊断制品中的应用
ITUB20160237A1 (it) * 2016-01-26 2017-07-26 Vision Engineering Italy Soc A Responsabilita Limitata Apparato di controllo del dosaggio di un agente cromoforo in un tessuto corneale e procedimento per dosare un agente cromoforo in un tessuto corneale
WO2017180851A1 (en) 2016-04-13 2017-10-19 Avedro, Inc. Systems and methods for delivering drugs to an eye
EP3585393A4 (en) * 2017-02-21 2020-12-30 Avedro, Inc. FORMULAS FOR EYE TREATMENTS
EP4260834B1 (en) 2018-03-05 2025-05-07 Avedro, Inc. System for eye tracking during eye treatment
WO2019173762A1 (en) 2018-03-08 2019-09-12 Avedro, Inc. Micro-devices for treatment of an eye
CN113329723A (zh) 2018-09-19 2021-08-31 艾维德洛公司 治疗角膜扩张型疾病的系统和方法
US12144546B2 (en) 2018-09-19 2024-11-19 Avedro, Inc. Systems and methods for eye tracking during eye treatment
CA3113120A1 (en) 2018-10-09 2020-04-16 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
WO2020176598A1 (en) 2019-02-26 2020-09-03 Avedro, Inc. Systems and methods for cross-linking treatments of an eye
US12226478B2 (en) 2019-04-28 2025-02-18 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11642244B2 (en) 2019-08-06 2023-05-09 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
CN110314034B (zh) * 2019-08-08 2021-12-03 南京市第一医院 一种可实现个性治疗的角膜交联装置
US11458220B2 (en) 2020-11-12 2022-10-04 Singletto Inc. Microbial disinfection for personal protection equipment
WO2022192237A1 (en) 2021-03-08 2022-09-15 Avedro, Inc. Systems and methods for generating patient-specific corneal cross-linking treatment patterns
CN115177729B (zh) * 2022-08-03 2023-09-26 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 肾上腺素受体激动剂在制备圆锥角膜交联促渗剂中的应用
US12359369B2 (en) 2022-08-11 2025-07-15 Singletto Inc. Skin protection against microbial particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
BR9908692A (pt) 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US7331350B2 (en) * 2000-02-11 2008-02-19 The General Hospital Corporation Photochemical tissue bonding
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
EP2464387A4 (en) * 2009-08-12 2013-05-15 Seros Medical Llc DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE

Also Published As

Publication number Publication date
IL211448A (en) 2016-05-31
JP2012500844A (ja) 2012-01-12
BRPI0910368A2 (pt) 2015-10-13
MX2011002234A (es) 2011-04-05
BRPI0910368B1 (pt) 2020-01-28
PT2323642E (pt) 2014-05-15
IL211448A0 (en) 2011-05-31
CN102164592A (zh) 2011-08-24
EA201100393A1 (ru) 2011-10-31
EA022055B1 (ru) 2015-10-30
DK2323642T3 (da) 2014-05-05
ES2460578T3 (es) 2014-05-13
WO2010023705A1 (en) 2010-03-04
US20110152219A1 (en) 2011-06-23
AU2009286285A1 (en) 2010-03-04
PL2323642T3 (pl) 2014-07-31
EP2323642B1 (en) 2014-02-19
MX358176B (es) 2018-08-08
EA201300272A1 (ru) 2013-07-30
EA023607B1 (ru) 2016-06-30
KR20110046567A (ko) 2011-05-04
CL2011000378A1 (es) 2011-06-10
EP2323642A1 (en) 2011-05-25
PE20110287A1 (es) 2011-05-15
IT1393402B1 (it) 2012-04-20
CN102164592B (zh) 2015-09-23
AU2009286285B2 (en) 2015-03-26
ITRM20080472A1 (it) 2010-02-28

Similar Documents

Publication Publication Date Title
BRPI0910368B8 (pt) uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
BR112013030583A2 (pt) materiais para lentes intraoculares acrílicas hidrofóbicas
CO6640285A2 (es) 5-alquinil-pirimidinas
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
UY32009A (es) 5-alquinil-pirimidinas
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
ECSP11010816A (es) Nuevos Compuestos
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
AR066732A1 (es) Lentes disenadas para el tratamiento de la astenopia causada por defectos visuales
MX384321B (es) Composición para administración oral de agentes bioactivos.
ECSP15018751A (es) Nuevas piridiloxialquilcarboxamidas y su uso como endoparasiticidas y nematicidas
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
CR20110022A (es) Nuevas posibilidades de lucha contra la giardiasis
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
Hirose et al. Decreasing and increasing marginal impatience and the terms of trade in an interdependent world economy
EA201590782A1 (ru) Оксирановые амины
BR112012010795A2 (pt) Formulações oftálmicas contendo gama lactams substituídas e métodos para uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF